Tandem Diabetes Care (TNDM) Depreciation & Amortization (CF) (2013 - 2026)

Tandem Diabetes Care (TNDM) has reported Depreciation & Amortization (CF) for 14 consecutive years, with $4.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Depreciation & Amortization (CF) rose 2.36% year-over-year to $4.5 million; the trailing twelve-month figure through Jun 2026 stood at $18.0 million (up 4.83% YoY), and the FY2025 full-year result was $17.7 million, up 6.38% from the prior year.
• Depreciation & Amortization (CF) fell to $4.5 million in Q2 2026 per TNDM's latest filing, from $4.5 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $4.5 million in Q1 2026 and bottomed at $3.4 million in Q1 2023.
• Historically, Depreciation & Amortization (CF) has averaged $4.1 million across 5 years, with a median of $4.2 million in 2024.
• The widest YoY moves for Depreciation & Amortization (CF): up 20.04% in 2023, down 6.39% in 2023.
• Over 5 years, Depreciation & Amortization (CF) stood at $3.6 million in 2022, then increased by 10.71% to $4.0 million in 2023, then rose by 5.31% to $4.2 million in 2024, then advanced by 5.89% to $4.5 million in 2025, then dropped by 0.56% to $4.5 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $4.5 million, $4.5 million, and $4.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.